Tesamorelin Research & Studies
Part of the full Tesamorelin guide - a synthetic growth hormone-releasing hormone reference compound, identity-verified with a COA on every vial.
In brief
Tesamorelin's research footprint in the provided record spans receptor pharmacology, signal-transduction biochemistry, enzymatic-stability kinetics, structure-activity work, and population pharmacokinetic modeling. The attached citations attribute specific aspects of the molecule to named sources: Tomlinson 2006 as a drug evaluation describing the synthetic GHRH analog and its DPP-4-resistance rationale; Dhillon 2011 as a review tied to GHRHR target characterization; Falutz et al. 2010 as the pooled phase 3 analysis that records the original development code TH9507; Stanley et al. 2014 as a randomized clinical trial; and Gonzalez-Sales et al. 2015 as a population pharmacokinetic analysis. The research-area list further organizes the in-vitro and modeling contexts in which the molecule is studied. Below, these sources and research areas are described strictly as the entry attributes them, without importing outcomes, numbers, or claims beyond what the provided record states, keeping the framing on receptor-level and laboratory investigation rather than any applied use.
The detail
A closer look
01
Receptor pharmacology and signal-transduction studies
Several listed research areas address tesamorelin at the molecular and cellular level. They include GHRH receptor (GHRHR) class B GPCR binding and agonist pharmacology; Gs/adenylyl cyclase/cAMP/PKA signal-transduction studies in somatotroph cell models; and CREB phosphorylation and growth-hormone gene transcription regulation. These define the in-vitro and cell-based contexts in which the molecule's signaling identity is characterized, mapping directly onto the cascade described in the mechanism record. The molecular-target keyfact, sourced to the Dhillon 2011 Drugs review and GHRH receptor pharmacology literature, names GHRHR, a class B GPCR on pituitary somatotrophs, as the target. Together these point to a research program in which agonist binding is studied at the receptor and the downstream second-messenger chain is read out in somatotroph cell models, consistent with the canonical GHRH signaling framework the entry describes.
02
Stability, degradation kinetics, and structure-activity work
Two research areas focus on the molecule's biochemical durability and design: DPP-4 enzymatic-stability and peptide-degradation kinetics of N-acylated GHRH analogs, and structure-activity relationships of N-terminal lipidation on GHRH-family peptides. These tie to the stabilizing-modification keyfact, which the entry sources to Tomlinson 2006 (Current Opinion in Investigational Drugs) and states that N-terminal hexenoyl acylation confers resistance to the DPP-4 cleavage that inactivates native GHRH. The peptide-backbone keyfact, attributed to Tomlinson 2006 and the PubChem description, records the full native GHRH(1-44) sequence with the N-terminal trans-3-hexenoyl modification on Tyr1. This cluster of sources supports research into how a defined N-acylation alters degradation kinetics relative to the unmodified peptide while the receptor-binding sequence is held constant.
03
Pharmacokinetic modeling and development-history sources
The record includes population/preclinical pharmacokinetic modeling of long-acting GHRH analogs as a research area, attributed in the citations to Gonzalez-Sales et al. 2015 in Clinical Pharmacokinetics, a population pharmacokinetic analysis. The Falutz et al. 2010 citation, a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety-extension data published in the Journal of Clinical Endocrinology and Metabolism, is the source the entry uses for the original development code TH9507 (TH-9507). Stanley et al. 2014 is listed as a randomized clinical trial published in JAMA. These three clinical and modeling sources are recorded here only as the provenance the entry assigns to specific facts and research areas; no outcome data from them appears in the entry, so they are referenced solely as the attributed origins of the molecule's pharmacokinetic-modeling context and development code.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Tesamorelin is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.